All stock lists
Unlock the score
AgomAb Therapeutics NV (NASDAQ:AGMB)
Belgium · Delayed Price · Currency is USD
Healthcare · Biotechnology
8.85-0.20 (-2.27%)
Insider Score
/ 100
AGMB Insider Score
AgomAb Therapeutics NV has a live Insider Score.
Scored on 10 qualifying trades from 3 insiders in the last 90 days.
AGMB Income Statement
| Fiscal Period | Q4 2025 | Q3 2025 | Q4 2024 |
|---|---|---|---|
| Period Ending | Dec 31, 2025 | Sep 30, 2025 | Dec 31, 2024 |
| Revenue | 0.00 | 0.00 | 0.00 |
| Revenue Growth (YoY) | — | — | — |
| Cost of Revenue | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 |
| SG&A Expense | 3.25 M | 2.64 M | 1.38 M |
| R&D Expense | 13.86 M | 12.99 M | 10.73 M |
| Operating Expenses | 16.53 M | 15.36 M | 11.81 M |
| Operating Income | -16.53 M | -15.36 M | -11.81 M |
| Pretax Income | -17.40 M | -18.28 M | -11.73 M |
| Tax Provision | 0.00 | 0.00 | 4.00 K |
| Net Income | -17.40 M | -18.28 M | -11.73 M |
| EPS (Basic) | -0.36 | -0.43 | -0.32 |
| EPS (Diluted) | -0.36 | -0.43 | -0.32 |
| Shares Outstanding | 48.74 M | 42.49 M | 36.24 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.